JP2022512374A5 - - Google Patents
Info
- Publication number
- JP2022512374A5 JP2022512374A5 JP2021533341A JP2021533341A JP2022512374A5 JP 2022512374 A5 JP2022512374 A5 JP 2022512374A5 JP 2021533341 A JP2021533341 A JP 2021533341A JP 2021533341 A JP2021533341 A JP 2021533341A JP 2022512374 A5 JP2022512374 A5 JP 2022512374A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- following
- pharmaceutical composition
- anxiety
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18212059 | 2018-12-12 | ||
| EP18212059.2 | 2018-12-12 | ||
| PCT/EP2019/084373 WO2020120449A1 (en) | 2018-12-12 | 2019-12-10 | Substituted xanthine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512374A JP2022512374A (ja) | 2022-02-03 |
| JP2022512374A5 true JP2022512374A5 (enExample) | 2022-12-16 |
| JP7408662B2 JP7408662B2 (ja) | 2024-01-05 |
Family
ID=64665183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533341A Active JP7408662B2 (ja) | 2018-12-12 | 2019-12-10 | 置換キサンタン誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12291532B2 (enExample) |
| EP (1) | EP3894409B1 (enExample) |
| JP (1) | JP7408662B2 (enExample) |
| CN (1) | CN113166150B (enExample) |
| WO (1) | WO2020120449A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12291532B2 (en) * | 2018-12-12 | 2025-05-06 | Boehringer Ingelheim International Gmbh | Substituted xanthines as modulators of TRPC5 activity |
| WO2024164818A1 (zh) * | 2023-02-08 | 2024-08-15 | 中国科学院上海药物研究所 | 黄嘌呤类化合物及其用途 |
| WO2024236027A1 (en) * | 2023-05-18 | 2024-11-21 | Boehringer Ingelheim International Gmbh | 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione for use in the treatment of borderline personality disorder |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107082782B (zh) | 2013-03-15 | 2020-03-20 | 海德拉生物科学有限责任公司 | 取代的黄嘌呤及其使用方法 |
| WO2016023830A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| GB201702160D0 (en) | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
| DK3652176T3 (da) * | 2017-07-11 | 2022-01-17 | Boehringer Ingelheim Int | Substituerede xanthinderivater |
| US12291532B2 (en) * | 2018-12-12 | 2025-05-06 | Boehringer Ingelheim International Gmbh | Substituted xanthines as modulators of TRPC5 activity |
-
2019
- 2019-12-10 US US17/312,831 patent/US12291532B2/en active Active
- 2019-12-10 CN CN201980081691.3A patent/CN113166150B/zh active Active
- 2019-12-10 JP JP2021533341A patent/JP7408662B2/ja active Active
- 2019-12-10 EP EP19820717.7A patent/EP3894409B1/en active Active
- 2019-12-10 WO PCT/EP2019/084373 patent/WO2020120449A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512374A5 (enExample) | ||
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| JP2016513663A5 (enExample) | ||
| JP2020526591A5 (enExample) | ||
| JP2017531020A5 (enExample) | ||
| JP2019525939A5 (enExample) | ||
| JP2020504156A5 (enExample) | ||
| JP2022512373A5 (enExample) | ||
| JP2008513516A5 (enExample) | ||
| JP2018070614A5 (enExample) | ||
| MXPA05012391A (es) | Tratamiento de trastornos psicoticos y depresivos. | |
| JP2020511461A5 (enExample) | ||
| JP2021531291A5 (enExample) | ||
| JP2007500757A5 (enExample) | ||
| JP2019532078A5 (enExample) | ||
| BR122017023795B8 (pt) | método para preparação de composição farmacêutica | |
| JP2005527593A5 (enExample) | ||
| JP2015523406A5 (enExample) | ||
| JP2007508358A5 (enExample) | ||
| JP2022515766A5 (enExample) | ||
| HRP20220029T1 (hr) | Supstituirani derivati ksantina | |
| JP2019516739A5 (enExample) | ||
| JP2018508592A5 (enExample) | ||
| JP2018505205A5 (enExample) | ||
| NO20073760L (no) | Triazolon-, tetrazolon- og imidazolonderivater for anvendelse som alfa-2C-adrenoreseptorantagonister |